US20080221648A1 - Combined photocoagulation and photodynamic therapy - Google Patents
Combined photocoagulation and photodynamic therapy Download PDFInfo
- Publication number
- US20080221648A1 US20080221648A1 US12/046,660 US4666008A US2008221648A1 US 20080221648 A1 US20080221648 A1 US 20080221648A1 US 4666008 A US4666008 A US 4666008A US 2008221648 A1 US2008221648 A1 US 2008221648A1
- Authority
- US
- United States
- Prior art keywords
- dye
- lesion
- treatment composition
- fluorescing
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F9/00821—Methods or devices for eye surgery using laser for coagulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
- A61F2009/00863—Retina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
Definitions
- This invention relates to a method for treating lesions, and more specifically where said lesion is an age related macular degeneration associated choroidal neovascularization, wherein said neovascularization is supplied by at least one blood vessel.
- Lesions are normally defined as an abnormal tissue structure located in an organ or other body part, and are often a manifestation of a harmful condition, disease or illness. Lesions may take many specific forms, such as choroidal neovascularizations (“CNVs”) which are found in the eye. In general, any abnormal vasculature in a body is a type of lesion.
- CNVs choroidal neovascularizations
- CNVs are routinely visualized using indocyanine green (“ICG”) dye angiography (“ICGA”). It is based on use of the near-infrared fluorescent light wavelengths emitted by ICG, which readily penetrate the pigmented ocular tissues.
- ICG indocyanine green
- ICGA dye angiography
- CNVs were treated by destruction of the entire CNV membrane using photocoagulation.
- Photocoagulation involves the application of energy, such as through a laser, sufficient to reduce the flow of blood through a target vessel or tissue.
- Photocoagulation of an entire CNV however, involved the destruction of a significant portion of the retina.
- Advances in the visualization of CNVs allowed for the ability to perform high-speed imaging. This led to the development of a current AMD treatment modality, namely CNV feeder vessel photocoagulation treatment.
- feeder vessel photocoagulation is performed by photocoagulating an afferent vessel supplying blood to a CNV. This reduces or stops the flow of blood to the CNV.
- feeder vessel photocoagulation an often smaller fundus area is photocoagulated since only the feeder vessel is targeted even when the CNV itself may be relatively large in area.
- the photocoagulation is often removed from the CNV, which may be juxta- or sub-foveal, thereby avoiding photocoagulation related damage to the fovea.
- One feeder vessel photocoagulation methodology also involves the use of a radiation absorbing dye, such as ICG.
- a radiation absorbing dye such as ICG.
- the presence of the radiation absorbing dye m a target blood vessel enhances the uptake of near-infrared laser energy and decreases the amount of laser energy required to photocoagulate the targeted vessel and is referred to as Dye-Enhanced Photocoagulation (“DEP”).
- DEP Dye-Enhanced Photocoagulation
- PDT photodynamic therapy
- a photodynamic agent into a subject, typically by intra-venous injection.
- energy e.g. light of a certain wavelength generated by a laser causing excitation of the agent.
- the agent When the agent is excited, it produces oxygen radicals which then attack the cells of the surrounding tissue, resulting in degradation of those cells.
- PDT destroys vascular endothelial cells of the CNV. This reduces, and preferably halts, the flow of blood within the CNV.
- PDT treatment may thus require multiple applications.
- concentration of PDT agent in the blood, rather than binding of PDT agent to the endothelium is more determinative of efficacy of PDT treatment.
- the non-target areas of the fundus may be subjected to more PDT-mediated damage than originally anticipated.
- PDT therapy traditionally involves infusing the PDT agent into a subject's vasculature, typically over about a ten (10) minute period. Infusion requires large quantities of PDT agent. Large quantities of PDT agent also translate into an increase in the likelihood of side effects, higher total cost and more light sensitivity post-treatment.
- the present invention provides a more effective method for wearing lesions, in an animal.
- the method of the present invention utilizes photocoagulation and PDT methodologies.
- One broad aspect of the inventive method contemplates treating a lesion by locating at least one vessel that supplies blood to the lesion, administering a treatment composition comprising a photodynamic agent to the subject, performing photocoagulation of said blood vessel to reduce the rate of blood flow through said blood vessel and thereby reduce the rate at which said treatment composition exits said lesion, and then performing PDT by exposing the lesion to radiation of an amount and type sufficient to activate the photodynamic agent and subject the lesion to PDT-mediated damage.
- the method is used to treat AMD-related CNVs.
- At least the partial presence of the PDT agent in the lesion is confirmed or approximated prior to photocoagulation of the feeder vessels.
- this approximation or confirmation is carried out by administering a fluorescing dye and taking at least one angiogram.
- a radiation absorbing dye is administered prior to photocoagulation of said blood vessel to improve said photocoagulation by using dye-enhanced photocoagulation.
- the photodynamic agent is administered along with a second dye that is both a fluorescing dye and a radiation absorbing dye, such as ICG, to treat AMD-related CNVs in a human.
- One advantage of the present invention is that by cutting off the blood flow using photocoagulation or DEP after administration of the PDT agent, the PDT agent becomes incarcerated in the lesion. This is significant as PDT agents, such as VisudyneTM, were previously thought to be held in the lesion during treatment because they were selectively bound to lesion tissues. However, it has come to light that PDT agents may not be as selectively bound to lesion tissues, such as CNVs, as originally anticipated. Therefore, by cutting off the blood flow to the lesion, once it has become at least partially filled with PDT agent, the PDT agent is physically held in the lesion for and during PDT.
- PDT agents such as VisudyneTM
- a further advantage is that the incarceration of the PDT agent in the lesion also allows the PDT agent in non-lesion areas to be flushed out at higher flush-out rates as compared to lesion areas. As a result, non-lesion areas will be subjected to less PDT mediated damage while maintaining PDT agent in the lesion area.
- a still further advantage is that the incarceration of PDT agent m the lesion increases the concentration of PDT agent in the lesion during treatment. A higher concentration of PDT agent in the lesion allows for more effective treatment.
- a still further advantage is that given that the PDT agent can be effectively concentrated in the lesion, the overall amounts of PDT agent used can be lowered. In the instance where PDT agent is infused, infusion time can therefore be correspondingly lowered. This is economically advantageous and decreases the likelihood of side effects resulting from the PDT agent.
- a still further advantage is that the reduction of blood flow through the feeder vessel enhances the rate of PDT-induced clot formation during PDT by reducing the movement and flow of blood through the lesion.
- a still further advantage is that, in the case of AMD-related CNV, post-PDT sensitivity to sunlight is significantly greatly reduced because of greatly reduced quantities of administered PDT agent.
- FIG. 1 illustrates, in flow chart form, a method for treating a lesion.
- FIG. 2 illustrates an overall system diagram implementing one embodiment of the inventive method.
- the lesion should further have a blood vessel that carries blood into the lesion.
- the method 10 includes the following steps. Locating a feeder vessel associated with a lesion 11 . Administering a composition comprising a photodynamic agent to the animal to fill at least a portion of the lesion with the composition 12 . Energy, such as a first treatment light is then applied to the feeder vessel, of sufficient type and amount to photocoagulate the feeder vessel thereby reducing the rate of blood flow in the feeder vessel and decreasing the rate at which the composition exits the lesion 13 .
- PDT is then performed by exposing the lesion to energy, such as a second treatment light, of a type and amount sufficient to excite the photodynamic dye 14 .
- energy such as a second treatment light
- Reducing, including stopping all together, the rate at which the composition, containing the PDT agent, exits a lesion is also referred to as “incarcerating”, “holding”, “maintaining”, “sequestering” or “trapping” the PDT agent in the lesion.
- incarcerating “holding”, “maintaining”, “sequestering” or “trapping” the PDT agent in the lesion.
- the inventive method is used to treat AMD related CNVs.
- locating a feeder vessel of a lesion 11 is accomplished by administering a fluorescent dye to an animal, applying energy of a type and amount sufficient to cause said dye to fluoresce, and obtaining at least one angiogram of a pre-selected area of interest containing the lesion.
- a CNV and its associated feeder vessels are visualized using Indocyanine Green Dye Fluorescence Angiography.
- ICG dye is administered to a subject intravenously and allowed to perfuse through the subject's vasculature. Visualization is preferably effected by irradiating a pre-selected area, containing the CNV, with a laser light of a type and in an amount sufficient to cause the ICG dye to fluoresce.
- a preferred dosage of ICG, for visualizing CNV feeder vessels is about 7.5 mg administered at a concentration of about 25 mg/ml in a volume of approximately 0.3 ml administered intravenously. Only one bolus is required per imaging sequence but multiple boluses may be employed. A concentration of about 0.025 mg/ml in blood theoretically produces the most fluorescence from the fundus of a mammalian eye. Additionally, in some embodiments of the invention, administration of ICG intravenously is followed by a 5 ml saline flush. The saline flush is used to rapidly push the bolus out of the cubital vein and into the thoracic cavity.
- Activation of ICG dye is preferably effected using a laser light source in the range of about 780 nm-830 nm.
- laser light used to excite dye fluorescence preferably irradiates a target site of about 1 cm 2 .
- Irradiation is preferably effected by irradiating the target area for about 10-20 seconds with a 1-4 ms pulse every 40 ms, each pulse having a peak power of about 300 mW to 700 mW. Typically, about 10 mW to 40 mW of average power is used.
- Capturing images of the fluorescing vasculature can be accomplished by numerous means which are known and will be apparent to a person skilled in the art. Images are preferably captured as high speed angiographic images on a CCD camera. The resultant images are analyzed to identify a lesion and feeder vessels associated with that lesion.
- a composition comprising a photodynamic dye is administered to the subject 12 .
- the photodynamic dye can be one or a combination of any of a number of available photodynamic agents.
- the agent selected should be capable of causing damage to a targeted tissue after exposure to an appropriate type of radiation, e.g. light of a certain wavelength, typically between about 630 nm and about 750 nm.
- an appropriate type of radiation e.g. light of a certain wavelength, typically between about 630 nm and about 750 nm.
- Many dyes that meet these criteria are available, and include, but are not limited to the following dyes, some of which are enumerated in U.S. Pat. No. 6,443,976:
- VisudyneTM is used as the photodynamic agent when treating a CNV in a human or mammalian eye.
- the photodynamic agent is administered along with a pharmaceutically acceptable carrier.
- the dose of photodynamic dye to be administered is that amount sufficient to, upon excitation, damage a specific target tissue.
- a photodynamic agent can be administered to a subject, including, but not limited to delivery via liposomes or intravenous injection, a dosage will vary accordingly.
- a preferred dosage of photodynamic agent will therefore depend on mode of delivery, type of agent, and composition.
- 15 mg of VisudyneTM is diluted in 7.5 ml to produce a 2 mg/ml solution. Dose for a subject is then calculated on the basis of surface area of 6 mg/m 2 Based on this, the appropriate amount is extracted from VisudyneTM solution and is diluted to 30 ml with 5% dextrose solution. The 30 ml of VisudyneTM solution is then infused over 8 minutes into the subject's vasculature.
- the photodynamic agent is delivered as a rapid bolus intravenously. Additionally, in this embodiment of the invention, administration of PDT agent is followed by a 5 ml saline flush. The saline flush is used to rapidly push the bolus out of the cubital vein and into the thoracic cavity.
- At least the partial presence of the PDT agent in the lesion is confirmed or at least approximated.
- a fluorescing dye is effective for fluorescence angiography and includes, but is not limited to, ICG. Energy sufficient to fluoresce the dye is applied and at least one angiographic image is then captured.
- the fluorescing dye is administered along with the PDT agent in the same treatment composition (i.e. as part of the same bolus or infusion mixture), then subsequent fluorescent angiography will show the presence of that bolus or mixture (and thus the PDT agent) in the lesion as indicated by fluorescence within said lesion. If the fluorescing dye is administered separately from the PDT agent, the presence of the PDT agent in the lesion can also be approximated by calculating the arrival of the PDT agent in the lesion depending on the pre-determined time lapse between the administration of the PDT agent and fluorescing dye.
- a radiation absorbing dye is prior to photocoagulation of the feeder vessel.
- Such dye is effective for dye-enhanced photocoagulation and includes, but is not limited to, ICG.
- the radiation absorbing dye can be administered separately or along with the photodynamic agent.
- VisudyneTM is preferably combined with ICG dye such that a 0.3 ml formulation has final concentration of about 65 mg/ml ICG.
- Intravenous administration of the bolus is followed by a 5 ml saline flush.
- ICG is both a fluorescing and radiation-absorbing dye.
- the practitioner can approximate or confirm the presence of the combined ICG/PDT agent formulation in the CNV while ICG also being effective for subsequent DEP. While these represent preferred values for a combined VisudyneTM and ICG bolus, it will be understood by those skilled in the art that other values are permissible and effective.
- photocoagulation of the feeder vessel of the lesion is performed 13 .
- Targeting of a photocoagulation treatment beam is based upon information previously derived from the locating of the feeder vessel associated with the lesion.
- Photocoagulation is effected by applying radiation of a kind and amount sufficient to effect an occlusion of a target feeder vessel. It is believed that such occlusion occurs by increasing the temperature of the feeder vessel, resulting in either cauterization of the feeder vessel or clotting of the blood within the feeder vessel. As a result, the rate of blood flow through the feeder vessel is reduced. Photocoagulation of a vessel results in the reduction in the rate of blood flow through such vessel, this includes but is not limited to halting blood flow completely.
- enhanced photocoagulation of the feeder vessel is effected by utilizing DEP.
- photocoagulation is enhanced by utilizing the radiation absorbing properties of the ICG dye to perform DEP of the feeder vessel.
- ICG can act as both the fluorescing dye and the radiation-absorbing dye.
- an approximately 810 nm treatment laser is used at about 400-600 mW for about 1.0-1.5 seconds to effect ICG DEP. This produces about 0.4J-0.9J of energy sufficient to photocoagulate the vessel in the presence of ICG.
- the photodynamic agent By photocoagulating a feeder vessel that supplies blood into a lesion just after the photodynamic agent has at least partially filled the lesion, the photodynamic agent is incarcerated in the lesion since the rate of fluid flow though the feeder vessel is reduced and thus the rate at which the PDT agent exits the lesion is also reduced.
- ICG is known to also have some photodynamic properties.
- ICG is used as a photodynamic agent, fluorescing dye and a radiation-absorbing dye.
- the photodynamic agent, fluorescing dye and the radiation-absorbing dye may each be delivered separately as rapid boluses intravenously, as a rapid single bolus, each infused over a defined period of time, or any combination thereof without departing from the spirit of the invention.
- Photodynamic therapy is then performed on the lesion 14 .
- the target tissue is irradiated with radiation of a type and amount sufficient to excite the PDT agent and damage the lesion.
- the radiation excites the PDT agent, now incarcerated in the lesion, effecting PDT treatment of the lesion.
- the rate at which PDT exits the lesion has been reduced.
- this confirmation can be achieved by applying energy to the area of the lesion and obtaining a subsequent angiographic image. If the PDT agent/fluorescing dye mixture is incarcerated in the lesion, vessels outside of the lesion will be subjected to regular flush out rates. Thus, the angiographic image will show fluorescence for vessels within the lesion with a marked decrease in fluorescence in vessels outside the lesion.
- confirmation can be achieved by first administering a fluorescing dye before applying the appropriate energy to fluoresce the dye and obtaining a subsequent angiographic image.
- the newly administered fluorescing dye will not be able to enter the lesion (or at least enter at a reduced rate).
- the angiographic image will show fluorescence for vessels outside the lesion with a marked decrease in fluorescence in vessels within the lesion.
- a lesion is therefore attacked on two fronts.
- This combined photocoagulation (preferably DEP)/PDT is not a simple serial application of both PDT and DEP, but an integrated method.
- This integrated method consisting of PDT and DEP methodologies in a predetermined order has new and unanticipated results, when compared to PDT and DEP performed separately.
- Photocoagulation is performed after at least one feeder vessel associated with a lesion has been identified and a photodynamic agent has been administered, but before application of PDT treatment radiation. Only after photocoagulation of the feeder vessel is the PDT radiation applied to a predetermined treatment area containing the lesion to effect activation of the PDT agent.
- the present invention of combined photocoagulation and PDT as outlined has several advantageous effects over and above the additive effect of the individual therapies alone. As outlined, this combined therapy exhibits advantageous synergistic effects.
- a system 200 is provided for implementing one preferred embodiment of the inventive method.
- a tool for administering a composition intravenously such as a syringe 231 is provided.
- a lesion 211 is supplied by a feeder vessel 210 , both shown magnified.
- a CCD camera 220 is provided.
- a computer system 226 comprises a CPU 222 , memory 221 , such as a hard disk and random access memory, an imaging processor 223 , a PC monitor 224 and one or more input devices 225 .
- a controller 227 is provided.
- a first laser 230 , a second laser 229 and a third laser 228 are provided.
- the identification of the feeder vessel 210 is carried out by injecting a patient intravenously with a fluorescent dye, preferably ICG, using the syringe 231 .
- Energy of a type and amount sufficient to cause the fluorescent dye in the blood vessels, in and around the lesion 211 , to fluoresce, is applied using the first laser 230 .
- the first laser 230 is controlled by the controller 227 that receives input signals from the CPU 222 .
- At least one angiographic image, of the fluorescing lesion 211 and the surrounding area, is then taken using the CCD camera 220 . Said angiographic image is stored in memory 221 and displayed on the monitor 224 using an imaging processor 223 , thus allowing a feeder vessel 210 to be identified.
- a treatment composition comprising a PDT agent and ICG dye is then administered intravenously using a syringe 231 .
- the presence of the treatment composition in the area corresponding to the lesion 211 and the feeder vessel 210 is confirmed by applying energy, using the first laser, of a type and amount sufficient to cause the ICG in the blood vessels of the lesion 211 and the feeder vessel 210 to fluoresce.
- An angiographic image is then taken using the CCD camera 220 and displayed on the monitor 224 as described above.
- the feeder vessel 210 is then photocoagulated by applying energy, of a type and amount sufficient to reduce the rate of blood flow through said feeder vessel 210 , using the second laser 229 .
- the second laser 229 is controlled by the controller 227 which receives input signals from the CPU 222 .
- the lesion 211 is then subjected to PDT by applying energy, of a type and amount sufficient to excite said PDT agent, using the third laser 228 .
- the third laser 228 is controlled by the controller 227 which receives input signals from the CPU 222 .
Abstract
Description
- This application claims priority from U.S. patent application Ser. No. 60/396146, filed Jul. 17, 2002.
- This invention relates to a method for treating lesions, and more specifically where said lesion is an age related macular degeneration associated choroidal neovascularization, wherein said neovascularization is supplied by at least one blood vessel.
- Lesions are normally defined as an abnormal tissue structure located in an organ or other body part, and are often a manifestation of a harmful condition, disease or illness. Lesions may take many specific forms, such as choroidal neovascularizations (“CNVs”) which are found in the eye. In general, any abnormal vasculature in a body is a type of lesion.
- Lesions must often be identified and visualized prior to treatment and such methods are known in the art. For example, CNVs are routinely visualized using indocyanine green (“ICG”) dye angiography (“ICGA”). It is based on use of the near-infrared fluorescent light wavelengths emitted by ICG, which readily penetrate the pigmented ocular tissues. Methods for enhancing visualization of CNVs (i.e. as taught in U.S. Pat. No. 5,394,199) are also known in the art.
- Traditionally, CNVs were treated by destruction of the entire CNV membrane using photocoagulation. Photocoagulation involves the application of energy, such as through a laser, sufficient to reduce the flow of blood through a target vessel or tissue. Photocoagulation of an entire CNV, however, involved the destruction of a significant portion of the retina. Advances in the visualization of CNVs allowed for the ability to perform high-speed imaging. This led to the development of a current AMD treatment modality, namely CNV feeder vessel photocoagulation treatment.
- Following visualization of a CNV feeder vessel (e.g. by ICGA), feeder vessel photocoagulation is performed by photocoagulating an afferent vessel supplying blood to a CNV. This reduces or stops the flow of blood to the CNV. With feeder vessel photocoagulation, an often smaller fundus area is photocoagulated since only the feeder vessel is targeted even when the CNV itself may be relatively large in area. Also, the photocoagulation is often removed from the CNV, which may be juxta- or sub-foveal, thereby avoiding photocoagulation related damage to the fovea.
- One feeder vessel photocoagulation methodology also involves the use of a radiation absorbing dye, such as ICG. The presence of the radiation absorbing dye m a target blood vessel enhances the uptake of near-infrared laser energy and decreases the amount of laser energy required to photocoagulate the targeted vessel and is referred to as Dye-Enhanced Photocoagulation (“DEP”). Thus, DEP reduces the amount of concomitant damage to the overlying sensory retina.
- Another example of a current method for Treating abnormal vasculature is photodynamic therapy (“PDT”). Generally, application of PDT requires administration of a photodynamic agent into a subject, typically by intra-venous injection. Once the agent arrives in a target site containing a tissue to be treated, the site is subjected to energy, e.g. light of a certain wavelength generated by a laser causing excitation of the agent. When the agent is excited, it produces oxygen radicals which then attack the cells of the surrounding tissue, resulting in degradation of those cells. By way of example, and in the case of CNV, PDT destroys vascular endothelial cells of the CNV. This reduces, and preferably halts, the flow of blood within the CNV.
- It is possible that in some cases, reperfusion occurs following initially successful PDT of a CNV. PDT treatment may thus require multiple applications. Moreover, it now appears that the extent to which many PDT agents are selective for abnormal vasculature may not be as high as originally expected. In other words, concentration of PDT agent in the blood, rather than binding of PDT agent to the endothelium, is more determinative of efficacy of PDT treatment. As a result, the non-target areas of the fundus may be subjected to more PDT-mediated damage than originally anticipated. Also, PDT therapy traditionally involves infusing the PDT agent into a subject's vasculature, typically over about a ten (10) minute period. Infusion requires large quantities of PDT agent. Large quantities of PDT agent also translate into an increase in the likelihood of side effects, higher total cost and more light sensitivity post-treatment.
- A need exists for improved methods of treatment of age-related macular degeneration associated choroidal neovascularizations and lesions generally.
- The present invention provides a more effective method for wearing lesions, in an animal. The method of the present invention utilizes photocoagulation and PDT methodologies. One broad aspect of the inventive method contemplates treating a lesion by locating at least one vessel that supplies blood to the lesion, administering a treatment composition comprising a photodynamic agent to the subject, performing photocoagulation of said blood vessel to reduce the rate of blood flow through said blood vessel and thereby reduce the rate at which said treatment composition exits said lesion, and then performing PDT by exposing the lesion to radiation of an amount and type sufficient to activate the photodynamic agent and subject the lesion to PDT-mediated damage. In one embodiment of the invention, the method is used to treat AMD-related CNVs.
- Preferably, at least the partial presence of the PDT agent in the lesion is confirmed or approximated prior to photocoagulation of the feeder vessels. In one embodiment, this approximation or confirmation is carried out by administering a fluorescing dye and taking at least one angiogram.
- In another embodiment of the invention, a radiation absorbing dye is administered prior to photocoagulation of said blood vessel to improve said photocoagulation by using dye-enhanced photocoagulation.
- In a preferred embodiment of the invention, the photodynamic agent is administered along with a second dye that is both a fluorescing dye and a radiation absorbing dye, such as ICG, to treat AMD-related CNVs in a human.
- Also provided is a system for treating lesions implementing one preferred embodiment of the inventive method.
- One advantage of the present invention is that by cutting off the blood flow using photocoagulation or DEP after administration of the PDT agent, the PDT agent becomes incarcerated in the lesion. This is significant as PDT agents, such as Visudyne™, were previously thought to be held in the lesion during treatment because they were selectively bound to lesion tissues. However, it has come to light that PDT agents may not be as selectively bound to lesion tissues, such as CNVs, as originally anticipated. Therefore, by cutting off the blood flow to the lesion, once it has become at least partially filled with PDT agent, the PDT agent is physically held in the lesion for and during PDT.
- A further advantage is that the incarceration of the PDT agent in the lesion also allows the PDT agent in non-lesion areas to be flushed out at higher flush-out rates as compared to lesion areas. As a result, non-lesion areas will be subjected to less PDT mediated damage while maintaining PDT agent in the lesion area.
- A still further advantage is that the incarceration of PDT agent m the lesion increases the concentration of PDT agent in the lesion during treatment. A higher concentration of PDT agent in the lesion allows for more effective treatment.
- A still further advantage is that given that the PDT agent can be effectively concentrated in the lesion, the overall amounts of PDT agent used can be lowered. In the instance where PDT agent is infused, infusion time can therefore be correspondingly lowered. This is economically advantageous and decreases the likelihood of side effects resulting from the PDT agent.
- A still further advantage is that the reduction of blood flow through the feeder vessel enhances the rate of PDT-induced clot formation during PDT by reducing the movement and flow of blood through the lesion.
- A still further advantage is that, in the case of AMD-related CNV, post-PDT sensitivity to sunlight is significantly greatly reduced because of greatly reduced quantities of administered PDT agent.
-
FIG. 1 illustrates, in flow chart form, a method for treating a lesion. -
FIG. 2 illustrates an overall system diagram implementing one embodiment of the inventive method. - In the following description, numerous specific details are set forth to provide a thorough understanding of the invention. However, it is understood that the invention may be practiced without these specific details. In other instances, well-known processes have not been described or shown in detail in order not to obscure the invention.
- The methods of the present invention are claimed and described herein as a series of treatment steps. It should be understood that these methods and associated steps may be performed in any logical order that preserves the spirit of the invention. Moreover, the methods may be performed alone, or in conjunction with other procedures and treatments administered before, during or after such methods and steps set forth herein without departing from the scope and spirit of the invention. Further, it is contemplated that the term animals as used herein includes, but is not limited to, humans.
- Achieving even more effective treatment of lesions, such as AMD-related CNV, lies in combining photocoagulation (or DEP) with PDT treatment methodologies.
- Referring to
FIG. 1 , a method for treating lesions according to one broad aspect of the invention is shown 10. The lesion should further have a blood vessel that carries blood into the lesion. Themethod 10 includes the following steps. Locating a feeder vessel associated with alesion 11. Administering a composition comprising a photodynamic agent to the animal to fill at least a portion of the lesion with thecomposition 12. Energy, such as a first treatment light is then applied to the feeder vessel, of sufficient type and amount to photocoagulate the feeder vessel thereby reducing the rate of blood flow in the feeder vessel and decreasing the rate at which the composition exits thelesion 13. PDT is then performed by exposing the lesion to energy, such as a second treatment light, of a type and amount sufficient to excite thephotodynamic dye 14. Reducing, including stopping all together, the rate at which the composition, containing the PDT agent, exits a lesion is also referred to as “incarcerating”, “holding”, “maintaining”, “sequestering” or “trapping” the PDT agent in the lesion. Further, it is understood that when referring to incarcerating the composition in the lesion, it is not necessary that all of the administered composition be incarcerated, but merely a proportion thereof. - In a preferred embodiment of the invention, the inventive method is used to treat AMD related CNVs.
- In one embodiment of the invention, locating a feeder vessel of a
lesion 11 is accomplished by administering a fluorescent dye to an animal, applying energy of a type and amount sufficient to cause said dye to fluoresce, and obtaining at least one angiogram of a pre-selected area of interest containing the lesion. In a further embodiment of the invention, a CNV and its associated feeder vessels are visualized using Indocyanine Green Dye Fluorescence Angiography. ICG dye is administered to a subject intravenously and allowed to perfuse through the subject's vasculature. Visualization is preferably effected by irradiating a pre-selected area, containing the CNV, with a laser light of a type and in an amount sufficient to cause the ICG dye to fluoresce. - A preferred dosage of ICG, for visualizing CNV feeder vessels, is about 7.5 mg administered at a concentration of about 25 mg/ml in a volume of approximately 0.3 ml administered intravenously. Only one bolus is required per imaging sequence but multiple boluses may be employed. A concentration of about 0.025 mg/ml in blood theoretically produces the most fluorescence from the fundus of a mammalian eye. Additionally, in some embodiments of the invention, administration of ICG intravenously is followed by a 5 ml saline flush. The saline flush is used to rapidly push the bolus out of the cubital vein and into the thoracic cavity.
- Activation of ICG dye is preferably effected using a laser light source in the range of about 780 nm-830 nm. When visualizing a CNV and its associated feeder vessels in a mammalian eye, laser light used to excite dye fluorescence preferably irradiates a target site of about 1 cm2. Irradiation is preferably effected by irradiating the target area for about 10-20 seconds with a 1-4 ms pulse every 40 ms, each pulse having a peak power of about 300 mW to 700 mW. Typically, about 10 mW to 40 mW of average power is used.
- Capturing images of the fluorescing vasculature can be accomplished by numerous means which are known and will be apparent to a person skilled in the art. Images are preferably captured as high speed angiographic images on a CCD camera. The resultant images are analyzed to identify a lesion and feeder vessels associated with that lesion.
- While the above represents preferred parameters for visualizing a CNV and identifying associated feeder vessels, it is well known in the art that other dosages are also effective to produce fluorescence in the eye such that a CNV and its associated feeder vessels can be identified and located.
- Following the locating of a feeder vessel associated with a lesion, a composition comprising a photodynamic dye is administered to the subject 12. The photodynamic dye can be one or a combination of any of a number of available photodynamic agents. The agent selected should be capable of causing damage to a targeted tissue after exposure to an appropriate type of radiation, e.g. light of a certain wavelength, typically between about 630 nm and about 750 nm. Many dyes that meet these criteria are available, and include, but are not limited to the following dyes, some of which are enumerated in U.S. Pat. No. 6,443,976:
-
- hematoporphyrins, which include derivatives thereof such as, e.g. dihematoporphyrins ethers and dimer and trimers of hematoporphyrins (examples of which are described in U.S. Pat. Nos. 4,968,715 and 5,190,966), and improvements thereon, examples of the latter being described in U.S. Pat. Nos. 5,028,621, 4,866,168, 4,649,151 and 5,438,071;
- aminolevulinic acids (precursors to hematoporphyrin) as sources of photodynamic compounds, as described and exemplified in U.S. Pat. No. 5,079,262;
- porphyrins, including boronated porphyrin, benzoporphyrin, and derivatives thereof, and as further exemplified by the green porphyrin described in U.S. Pat. Nos. 4,883,790, 4,920,143, 5,095,030 and 5,171,749;
- mercocyanines;
- porphycenes;
- porfimer sodium;
- indocyanine green
- verteporfin (Visudyne™, CIBA Vision);
- Photofrin II™;
- PH-10™;
- chlorins, as exemplified by meso-tetra(hydroxyphenyl)-chlorin and bacteriochlorins, the latter exmplified in U.S. Pat. Nos. 5,171,741, 5,173,504;
- zinc phthalocyanine, as described in U.S. Pat. No. 5,166,197;
- purpurins, such as tin ethyl eriopurpurin (SnET2™, Miravant);
- pheophorbides, examples of which are described in U.S. Pat. Nos. 5,198,460, 5,002,962 and 5,093,349; and
- monoclonal antibody-dye conjugates of each of the foregoing.
- In one preferred embodiment, Visudyne™ is used as the photodynamic agent when treating a CNV in a human or mammalian eye. In some embodiments of the invention, the photodynamic agent is administered along with a pharmaceutically acceptable carrier.
- The dose of photodynamic dye to be administered is that amount sufficient to, upon excitation, damage a specific target tissue. Given the various acceptable ways that a photodynamic agent can be administered to a subject, including, but not limited to delivery via liposomes or intravenous injection, a dosage will vary accordingly. A preferred dosage of photodynamic agent will therefore depend on mode of delivery, type of agent, and composition.
- In one embodiment of the invention, 15 mg of Visudyne™ is diluted in 7.5 ml to produce a 2 mg/ml solution. Dose for a subject is then calculated on the basis of surface area of 6 mg/m2 Based on this, the appropriate amount is extracted from Visudyne™ solution and is diluted to 30 ml with 5% dextrose solution. The 30 ml of Visudyne™ solution is then infused over 8 minutes into the subject's vasculature.
- In another embodiment of the invention, the photodynamic agent is delivered as a rapid bolus intravenously. Additionally, in this embodiment of the invention, administration of PDT agent is followed by a 5 ml saline flush. The saline flush is used to rapidly push the bolus out of the cubital vein and into the thoracic cavity.
- In one preferred embodiment of the invention, after administering the PDT agent but prior to photocoagulation of the feeder vessel, at least the partial presence of the PDT agent in the lesion is confirmed or at least approximated. This can be achieved by administering a fluorescing dye separately or along with the photodynamic agent but prior to photocoagulation of the feeder vessel. Such dye is effective for fluorescence angiography and includes, but is not limited to, ICG. Energy sufficient to fluoresce the dye is applied and at least one angiographic image is then captured.
- If the fluorescing dye is administered along with the PDT agent in the same treatment composition (i.e. as part of the same bolus or infusion mixture), then subsequent fluorescent angiography will show the presence of that bolus or mixture (and thus the PDT agent) in the lesion as indicated by fluorescence within said lesion. If the fluorescing dye is administered separately from the PDT agent, the presence of the PDT agent in the lesion can also be approximated by calculating the arrival of the PDT agent in the lesion depending on the pre-determined time lapse between the administration of the PDT agent and fluorescing dye.
- In another preferred embodiment of the invention, a radiation absorbing dye is prior to photocoagulation of the feeder vessel. Such dye is effective for dye-enhanced photocoagulation and includes, but is not limited to, ICG. The radiation absorbing dye can be administered separately or along with the photodynamic agent.
- In treating CNVs, Visudyne™ is preferably combined with ICG dye such that a 0.3 ml formulation has final concentration of about 65 mg/ml ICG. Intravenous administration of the bolus is followed by a 5 ml saline flush. Advantageously, ICG is both a fluorescing and radiation-absorbing dye. By irradiating the fundus of the eye with radiation sufficient to fluoresce the ICG dye, the practitioner can approximate or confirm the presence of the combined ICG/PDT agent formulation in the CNV while ICG also being effective for subsequent DEP. While these represent preferred values for a combined Visudyne™ and ICG bolus, it will be understood by those skilled in the art that other values are permissible and effective.
- Following administration of a photodynamic agent such that the lesion is at least partially filled with an effective amount of photodynamic agent, photocoagulation of the feeder vessel of the lesion is performed 13. Targeting of a photocoagulation treatment beam is based upon information previously derived from the locating of the feeder vessel associated with the lesion. Photocoagulation is effected by applying radiation of a kind and amount sufficient to effect an occlusion of a target feeder vessel. It is believed that such occlusion occurs by increasing the temperature of the feeder vessel, resulting in either cauterization of the feeder vessel or clotting of the blood within the feeder vessel. As a result, the rate of blood flow through the feeder vessel is reduced. Photocoagulation of a vessel results in the reduction in the rate of blood flow through such vessel, this includes but is not limited to halting blood flow completely.
- In embodiments of the invention where a radiation absorbing dye is administered, enhanced photocoagulation of the feeder vessel is effected by utilizing DEP. In the preferred embodiment wherein a combined bolus of ICG dye and Visudyne™ is administered, photocoagulation is enhanced by utilizing the radiation absorbing properties of the ICG dye to perform DEP of the feeder vessel. Thus, in this embodiment, ICG can act as both the fluorescing dye and the radiation-absorbing dye. Preferably, an approximately 810 nm treatment laser is used at about 400-600 mW for about 1.0-1.5 seconds to effect ICG DEP. This produces about 0.4J-0.9J of energy sufficient to photocoagulate the vessel in the presence of ICG.
- By photocoagulating a feeder vessel that supplies blood into a lesion just after the photodynamic agent has at least partially filled the lesion, the photodynamic agent is incarcerated in the lesion since the rate of fluid flow though the feeder vessel is reduced and thus the rate at which the PDT agent exits the lesion is also reduced.
- ICG is known to also have some photodynamic properties. Thus, in some embodiments of the invention, ICG is used as a photodynamic agent, fluorescing dye and a radiation-absorbing dye.
- The photodynamic agent, fluorescing dye and the radiation-absorbing dye may each be delivered separately as rapid boluses intravenously, as a rapid single bolus, each infused over a defined period of time, or any combination thereof without departing from the spirit of the invention.
- Photodynamic therapy is then performed on the
lesion 14. The target tissue is irradiated with radiation of a type and amount sufficient to excite the PDT agent and damage the lesion. Thus, the radiation excites the PDT agent, now incarcerated in the lesion, effecting PDT treatment of the lesion. - In one embodiment of the invention, after photocoagulation of the feeder vessel but prior to PDT, there is an additional step of confirming that the rate at which PDT exits the lesion has been reduced. In those embodiments where a fluorescing dye was administered along with the PDT agent, this confirmation can be achieved by applying energy to the area of the lesion and obtaining a subsequent angiographic image. If the PDT agent/fluorescing dye mixture is incarcerated in the lesion, vessels outside of the lesion will be subjected to regular flush out rates. Thus, the angiographic image will show fluorescence for vessels within the lesion with a marked decrease in fluorescence in vessels outside the lesion. In those embodiments where no fluorescing dye was administered prior to photocoagulation, then confirmation can be achieved by first administering a fluorescing dye before applying the appropriate energy to fluoresce the dye and obtaining a subsequent angiographic image. In this case, since the feeder vessel has been photocoagulated, the newly administered fluorescing dye will not be able to enter the lesion (or at least enter at a reduced rate). Thus, the angiographic image will show fluorescence for vessels outside the lesion with a marked decrease in fluorescence in vessels within the lesion.
- Typical parameters for photocoagulation, DEP and PDT have been provided as preferred values and should not be construed as a limitation on the claims of the present invention. It will be apparent to those skilled in the art that other parameters are permissible and effective to work the invention.
- A lesion is therefore attacked on two fronts. First, the lesion's blood supply is cut off using photocoagulation or DEP. This has the effect of starving the lesion and immediately reducing the hemodynamic pressure. Second, the abnormal vasculature itself is targeted by PDT. Excitation of the photodynamic agent present in the lesion additionally damages the lesion directly.
- This combined photocoagulation (preferably DEP)/PDT is not a simple serial application of both PDT and DEP, but an integrated method. This integrated method, consisting of PDT and DEP methodologies in a predetermined order has new and unanticipated results, when compared to PDT and DEP performed separately.
- Photocoagulation is performed after at least one feeder vessel associated with a lesion has been identified and a photodynamic agent has been administered, but before application of PDT treatment radiation. Only after photocoagulation of the feeder vessel is the PDT radiation applied to a predetermined treatment area containing the lesion to effect activation of the PDT agent.
- Significantly, the present invention of combined photocoagulation and PDT as outlined has several advantageous effects over and above the additive effect of the individual therapies alone. As outlined, this combined therapy exhibits advantageous synergistic effects.
- Referring to
FIG. 2 , asystem 200 is provided for implementing one preferred embodiment of the inventive method. A tool for administering a composition intravenously such as asyringe 231 is provided. Alesion 211 is supplied by afeeder vessel 210, both shown magnified. ACCD camera 220 is provided. Acomputer system 226 comprises aCPU 222,memory 221, such as a hard disk and random access memory, animaging processor 223, aPC monitor 224 and one ormore input devices 225. Acontroller 227 is provided. Afirst laser 230, asecond laser 229 and athird laser 228 are provided. - In practice, the identification of the
feeder vessel 210 is carried out by injecting a patient intravenously with a fluorescent dye, preferably ICG, using thesyringe 231. Energy, of a type and amount sufficient to cause the fluorescent dye in the blood vessels, in and around thelesion 211, to fluoresce, is applied using thefirst laser 230. Thefirst laser 230 is controlled by thecontroller 227 that receives input signals from theCPU 222. At least one angiographic image, of thefluorescing lesion 211 and the surrounding area, is then taken using theCCD camera 220. Said angiographic image is stored inmemory 221 and displayed on themonitor 224 using animaging processor 223, thus allowing afeeder vessel 210 to be identified. - A treatment composition, comprising a PDT agent and ICG dye is then administered intravenously using a
syringe 231. The presence of the treatment composition in the area corresponding to thelesion 211 and thefeeder vessel 210, is confirmed by applying energy, using the first laser, of a type and amount sufficient to cause the ICG in the blood vessels of thelesion 211 and thefeeder vessel 210 to fluoresce. An angiographic image is then taken using theCCD camera 220 and displayed on themonitor 224 as described above. - The
feeder vessel 210 is then photocoagulated by applying energy, of a type and amount sufficient to reduce the rate of blood flow through saidfeeder vessel 210, using thesecond laser 229. Thesecond laser 229 is controlled by thecontroller 227 which receives input signals from theCPU 222. - The
lesion 211 is then subjected to PDT by applying energy, of a type and amount sufficient to excite said PDT agent, using thethird laser 228. Thethird laser 228 is controlled by thecontroller 227 which receives input signals from theCPU 222. - Although the invention has been described with reference to certain specific embodiments, various modifications thereof will be apparent to those skilled in the art without departing from the spirit and scope of the invention as outlined in the claims appended hereto.
Claims (25)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/046,660 US20080221648A1 (en) | 2002-07-17 | 2008-03-12 | Combined photocoagulation and photodynamic therapy |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39614602P | 2002-07-17 | 2002-07-17 | |
US10/619,548 US7364574B2 (en) | 2002-07-17 | 2003-07-16 | Combined photocoagulation and photodynamic therapy |
US12/046,660 US20080221648A1 (en) | 2002-07-17 | 2008-03-12 | Combined photocoagulation and photodynamic therapy |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/619,548 Division US7364574B2 (en) | 2002-07-17 | 2003-07-16 | Combined photocoagulation and photodynamic therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080221648A1 true US20080221648A1 (en) | 2008-09-11 |
Family
ID=30115979
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/619,548 Expired - Fee Related US7364574B2 (en) | 2002-07-17 | 2003-07-16 | Combined photocoagulation and photodynamic therapy |
US12/046,660 Abandoned US20080221648A1 (en) | 2002-07-17 | 2008-03-12 | Combined photocoagulation and photodynamic therapy |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/619,548 Expired - Fee Related US7364574B2 (en) | 2002-07-17 | 2003-07-16 | Combined photocoagulation and photodynamic therapy |
Country Status (6)
Country | Link |
---|---|
US (2) | US7364574B2 (en) |
EP (1) | EP1539067B1 (en) |
AT (1) | ATE535219T1 (en) |
AU (1) | AU2003249807A1 (en) |
CA (1) | CA2499469C (en) |
WO (1) | WO2004006816A2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9204830B2 (en) | 2005-04-15 | 2015-12-08 | Surgisense Corporation | Surgical instruments with sensors for detecting tissue properties, and system using such instruments |
US9420967B2 (en) | 2013-03-19 | 2016-08-23 | Surgisense Corporation | Apparatus, systems and methods for determining tissue oxygenation |
US9610021B2 (en) | 2008-01-25 | 2017-04-04 | Novadaq Technologies Inc. | Method for evaluating blush in myocardial tissue |
US9816930B2 (en) | 2014-09-29 | 2017-11-14 | Novadaq Technologies Inc. | Imaging a target fluorophore in a biological material in the presence of autofluorescence |
US10041042B2 (en) | 2008-05-02 | 2018-08-07 | Novadaq Technologies ULC | Methods for production and use of substance-loaded erythrocytes (S-IEs) for observation and treatment of microvascular hemodynamics |
US10219742B2 (en) | 2008-04-14 | 2019-03-05 | Novadaq Technologies ULC | Locating and analyzing perforator flaps for plastic and reconstructive surgery |
US10265419B2 (en) | 2005-09-02 | 2019-04-23 | Novadaq Technologies ULC | Intraoperative determination of nerve location |
US10278585B2 (en) | 2012-06-21 | 2019-05-07 | Novadaq Technologies ULC | Quantification and analysis of angiography and perfusion |
US10434190B2 (en) | 2006-09-07 | 2019-10-08 | Novadaq Technologies ULC | Pre-and-intra-operative localization of penile sentinel nodes |
US10492671B2 (en) | 2009-05-08 | 2019-12-03 | Novadaq Technologies ULC | Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest |
US10631746B2 (en) | 2014-10-09 | 2020-04-28 | Novadaq Technologies ULC | Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography |
US10992848B2 (en) | 2017-02-10 | 2021-04-27 | Novadaq Technologies ULC | Open-field handheld fluorescence imaging systems and methods |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1731087A3 (en) | 2000-07-14 | 2008-08-06 | Novadaq Technologies Inc. | Compact fluorescent endoscopy video system |
US20060241496A1 (en) | 2002-01-15 | 2006-10-26 | Xillix Technologies Corp. | Filter for use with imaging endoscopes |
WO2005048826A1 (en) | 2003-11-20 | 2005-06-02 | Hamamatsu Photonics K.K. | Lymph node detector |
DE102004015682B4 (en) * | 2004-03-26 | 2008-07-31 | Bundesrepublik Deutschland, vertr. d. d. Bundesministerium für Wirtschaft und Technologie, dieses vertr. d. d. Präsidenten der Physikalisch-Technischen Bundesanstalt | Method and device for detecting a dye bolus injected into the body of a living being |
JP2006014868A (en) | 2004-06-30 | 2006-01-19 | Hamamatsu Photonics Kk | Lymph node detecting apparatus |
US8185176B2 (en) * | 2005-04-26 | 2012-05-22 | Novadaq Technologies, Inc. | Method and apparatus for vasculature visualization with applications in neurosurgery and neurology |
CA2618443A1 (en) * | 2005-08-10 | 2007-02-15 | Novadaq Technologies, Inc. | Intra-operative head & neck nerve mapping |
WO2007106624A2 (en) | 2006-02-07 | 2007-09-20 | Novadaq Technologies Inc. | Near infrared imaging |
US7465312B2 (en) * | 2006-05-02 | 2008-12-16 | Green Medical, Inc. | Systems and methods for treating superficial venous malformations like spider veins |
US20070299431A1 (en) * | 2006-05-02 | 2007-12-27 | Green Medical, Inc. | Systems and methods for treating superficial venous malformations like spider veins |
AU2007319871B2 (en) | 2006-11-10 | 2011-04-14 | Topcon Medical Laser Systems, Inc. | System and method for determining dosimetry in ophthalmic photomedicine |
US8409182B2 (en) | 2007-09-28 | 2013-04-02 | Eos Holdings, Llc | Laser-assisted thermal separation of tissue |
US20100241058A1 (en) * | 2009-03-19 | 2010-09-23 | Ahmed Syed Yosuf | Oct guided tissue ablation |
US20100256125A1 (en) * | 2009-04-06 | 2010-10-07 | Zila Pharmaceuticals, Inc. | Use of improved toluidine blue in photodynamic therapy |
US10327951B2 (en) | 2014-02-28 | 2019-06-25 | Excel-Lens, Inc. | Laser assisted cataract surgery |
US9820886B2 (en) | 2014-02-28 | 2017-11-21 | Excel-Lens, Inc. | Laser assisted cataract surgery |
US10206817B2 (en) | 2014-02-28 | 2019-02-19 | Excel-Lens, Inc. | Laser assisted cataract surgery |
US10231872B2 (en) | 2014-02-28 | 2019-03-19 | Excel-Lens, Inc. | Laser assisted cataract surgery |
US10293122B2 (en) | 2016-03-17 | 2019-05-21 | Novadaq Technologies ULC | Endoluminal introducer with contamination avoidance |
Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5279298A (en) * | 1992-11-20 | 1994-01-18 | The Johns Hopkins University | Method and apparatus to identify and treat neovascular membranes in the eye |
US5394199A (en) * | 1993-05-17 | 1995-02-28 | The Johns Hopkins University | Methods and apparatus for improved visualization of choroidal blood flow and aberrant vascular structures in the eye using fluorescent dye angiography |
US5576013A (en) * | 1995-03-21 | 1996-11-19 | Eastern Virginia Medical School | Treating vascular and neoplastic tissues |
US5662644A (en) * | 1996-05-14 | 1997-09-02 | Mdlt, Inc. | Dermatological laser apparatus and method |
US5707986A (en) * | 1994-03-14 | 1998-01-13 | Miller; Joan W. | Angiographic method using green porphyrins in primate eyes |
US5756541A (en) * | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
US5935942A (en) * | 1994-12-14 | 1999-08-10 | Zeimer; Ran | Selective and non-invasive visualization or treatment of vasculature |
US6162242A (en) * | 1999-01-21 | 2000-12-19 | Peyman; Gholam A. | Selective photodynamic treatment |
US6186628B1 (en) * | 1999-05-23 | 2001-02-13 | Jozek F. Van de Velde | Scanning laser ophthalmoscope for selective therapeutic laser |
US6238426B1 (en) * | 1999-07-19 | 2001-05-29 | Light Sciences Corporation | Real-time monitoring of photodynamic therapy over an extended time |
US6319273B1 (en) * | 1999-12-16 | 2001-11-20 | Light Sciences Corporation | Illuminating device for treating eye disease |
US6351663B1 (en) * | 1999-09-10 | 2002-02-26 | Akorn, Inc. | Methods for diagnosing and treating conditions associated with abnormal vasculature using fluorescent dye angiography and dye-enhanced photocoagulation |
US6351667B1 (en) * | 1997-10-24 | 2002-02-26 | Pulsion Medical Systems Ag | Device for detecting pericardial effusion |
US20020099279A1 (en) * | 2000-11-28 | 2002-07-25 | Pfeiffer Ulrich J. | Device for the determination of tissue perfusion and operative use thereof |
US6443976B1 (en) * | 1999-11-30 | 2002-09-03 | Akorn, Inc. | Methods for treating conditions and illnesses associated with abnormal vasculature |
US20030060718A1 (en) * | 1999-09-10 | 2003-03-27 | Akorn, Inc. | Indocyanine green (ICG) compositions and related methods of use |
US20030060722A1 (en) * | 2001-09-07 | 2003-03-27 | Pulsion Medical Systems Ag | System and a computer program for the determination of quantities relating to the circulatory system of a patient |
US20030093065A1 (en) * | 2001-11-13 | 2003-05-15 | Peyman Gholam A. | Method to treat age-related macular degeneration |
US20030093064A1 (en) * | 2001-11-13 | 2003-05-15 | Peyman Gholam A. | Method to treat age-related macular degeneration |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9903394D0 (en) * | 1999-02-15 | 1999-04-07 | Avimo Group Limited | Treatment of neovascularization and other eye diseases |
-
2003
- 2003-07-16 EP EP03763550A patent/EP1539067B1/en not_active Expired - Lifetime
- 2003-07-16 US US10/619,548 patent/US7364574B2/en not_active Expired - Fee Related
- 2003-07-16 WO PCT/CA2003/001071 patent/WO2004006816A2/en not_active Application Discontinuation
- 2003-07-16 AU AU2003249807A patent/AU2003249807A1/en not_active Abandoned
- 2003-07-16 AT AT03763550T patent/ATE535219T1/en active
- 2003-07-16 CA CA2499469A patent/CA2499469C/en not_active Expired - Fee Related
-
2008
- 2008-03-12 US US12/046,660 patent/US20080221648A1/en not_active Abandoned
Patent Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5279298A (en) * | 1992-11-20 | 1994-01-18 | The Johns Hopkins University | Method and apparatus to identify and treat neovascular membranes in the eye |
US5394199A (en) * | 1993-05-17 | 1995-02-28 | The Johns Hopkins University | Methods and apparatus for improved visualization of choroidal blood flow and aberrant vascular structures in the eye using fluorescent dye angiography |
US5707986A (en) * | 1994-03-14 | 1998-01-13 | Miller; Joan W. | Angiographic method using green porphyrins in primate eyes |
US6140314A (en) * | 1994-12-14 | 2000-10-31 | The Johns Hopkins University | Selective and non-invasive visualization or treatment of vasculature |
US6440950B1 (en) * | 1994-12-14 | 2002-08-27 | The Johns Hopkins University | Selective and non-invasive visualization or treatment of vasculature |
US6248727B1 (en) * | 1994-12-14 | 2001-06-19 | The Johns Hopkins University | Selective and non-invasive visualization or treatment of vasculature |
US5935942A (en) * | 1994-12-14 | 1999-08-10 | Zeimer; Ran | Selective and non-invasive visualization or treatment of vasculature |
US5576013A (en) * | 1995-03-21 | 1996-11-19 | Eastern Virginia Medical School | Treating vascular and neoplastic tissues |
US5910510A (en) * | 1996-03-11 | 1999-06-08 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
US5756541A (en) * | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
US5662644A (en) * | 1996-05-14 | 1997-09-02 | Mdlt, Inc. | Dermatological laser apparatus and method |
US6351667B1 (en) * | 1997-10-24 | 2002-02-26 | Pulsion Medical Systems Ag | Device for detecting pericardial effusion |
US6162242A (en) * | 1999-01-21 | 2000-12-19 | Peyman; Gholam A. | Selective photodynamic treatment |
US6186628B1 (en) * | 1999-05-23 | 2001-02-13 | Jozek F. Van de Velde | Scanning laser ophthalmoscope for selective therapeutic laser |
US6238426B1 (en) * | 1999-07-19 | 2001-05-29 | Light Sciences Corporation | Real-time monitoring of photodynamic therapy over an extended time |
US20030060718A1 (en) * | 1999-09-10 | 2003-03-27 | Akorn, Inc. | Indocyanine green (ICG) compositions and related methods of use |
US6351663B1 (en) * | 1999-09-10 | 2002-02-26 | Akorn, Inc. | Methods for diagnosing and treating conditions associated with abnormal vasculature using fluorescent dye angiography and dye-enhanced photocoagulation |
US6944493B2 (en) * | 1999-09-10 | 2005-09-13 | Akora, Inc. | Indocyanine green (ICG) compositions and related methods of use |
US6443976B1 (en) * | 1999-11-30 | 2002-09-03 | Akorn, Inc. | Methods for treating conditions and illnesses associated with abnormal vasculature |
US6319273B1 (en) * | 1999-12-16 | 2001-11-20 | Light Sciences Corporation | Illuminating device for treating eye disease |
US20020099279A1 (en) * | 2000-11-28 | 2002-07-25 | Pfeiffer Ulrich J. | Device for the determination of tissue perfusion and operative use thereof |
US20030060722A1 (en) * | 2001-09-07 | 2003-03-27 | Pulsion Medical Systems Ag | System and a computer program for the determination of quantities relating to the circulatory system of a patient |
US20030093065A1 (en) * | 2001-11-13 | 2003-05-15 | Peyman Gholam A. | Method to treat age-related macular degeneration |
US20030093064A1 (en) * | 2001-11-13 | 2003-05-15 | Peyman Gholam A. | Method to treat age-related macular degeneration |
US6936043B2 (en) * | 2001-11-13 | 2005-08-30 | Minu, Llc | Method to treat age-related macular degeneration |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11517213B2 (en) | 2005-04-15 | 2022-12-06 | Surgisense Corporation | Surgical instruments with sensors for detecting tissue properties, and system using such instruments |
US9204830B2 (en) | 2005-04-15 | 2015-12-08 | Surgisense Corporation | Surgical instruments with sensors for detecting tissue properties, and system using such instruments |
US10231634B2 (en) | 2005-04-15 | 2019-03-19 | Surgisense Corporation | Surgical instruments with sensors for detecting tissue properties, and system using such instruments |
US11324412B2 (en) | 2005-04-15 | 2022-05-10 | Surgisense Coporation | Surgical instruments with sensors for detecting tissue properties, and system using such instruments |
US10265419B2 (en) | 2005-09-02 | 2019-04-23 | Novadaq Technologies ULC | Intraoperative determination of nerve location |
US10434190B2 (en) | 2006-09-07 | 2019-10-08 | Novadaq Technologies ULC | Pre-and-intra-operative localization of penile sentinel nodes |
US10835138B2 (en) | 2008-01-25 | 2020-11-17 | Stryker European Operations Limited | Method for evaluating blush in myocardial tissue |
US11564583B2 (en) | 2008-01-25 | 2023-01-31 | Stryker European Operations Limited | Method for evaluating blush in myocardial tissue |
US9610021B2 (en) | 2008-01-25 | 2017-04-04 | Novadaq Technologies Inc. | Method for evaluating blush in myocardial tissue |
US9936887B2 (en) | 2008-01-25 | 2018-04-10 | Novadaq Technologies ULC | Method for evaluating blush in myocardial tissue |
US10219742B2 (en) | 2008-04-14 | 2019-03-05 | Novadaq Technologies ULC | Locating and analyzing perforator flaps for plastic and reconstructive surgery |
US10041042B2 (en) | 2008-05-02 | 2018-08-07 | Novadaq Technologies ULC | Methods for production and use of substance-loaded erythrocytes (S-IEs) for observation and treatment of microvascular hemodynamics |
US10492671B2 (en) | 2009-05-08 | 2019-12-03 | Novadaq Technologies ULC | Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest |
US11284801B2 (en) | 2012-06-21 | 2022-03-29 | Stryker European Operations Limited | Quantification and analysis of angiography and perfusion |
US10278585B2 (en) | 2012-06-21 | 2019-05-07 | Novadaq Technologies ULC | Quantification and analysis of angiography and perfusion |
US9420967B2 (en) | 2013-03-19 | 2016-08-23 | Surgisense Corporation | Apparatus, systems and methods for determining tissue oxygenation |
US10488340B2 (en) | 2014-09-29 | 2019-11-26 | Novadaq Technologies ULC | Imaging a target fluorophore in a biological material in the presence of autofluorescence |
US9816930B2 (en) | 2014-09-29 | 2017-11-14 | Novadaq Technologies Inc. | Imaging a target fluorophore in a biological material in the presence of autofluorescence |
US10631746B2 (en) | 2014-10-09 | 2020-04-28 | Novadaq Technologies ULC | Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography |
US10992848B2 (en) | 2017-02-10 | 2021-04-27 | Novadaq Technologies ULC | Open-field handheld fluorescence imaging systems and methods |
US11140305B2 (en) | 2017-02-10 | 2021-10-05 | Stryker European Operations Limited | Open-field handheld fluorescence imaging systems and methods |
Also Published As
Publication number | Publication date |
---|---|
CA2499469C (en) | 2013-06-04 |
EP1539067B1 (en) | 2011-11-30 |
AU2003249807A1 (en) | 2004-02-02 |
WO2004006816A2 (en) | 2004-01-22 |
US20040206364A1 (en) | 2004-10-21 |
ATE535219T1 (en) | 2011-12-15 |
CA2499469A1 (en) | 2004-01-22 |
EP1539067A1 (en) | 2005-06-15 |
US7364574B2 (en) | 2008-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7364574B2 (en) | Combined photocoagulation and photodynamic therapy | |
US6443976B1 (en) | Methods for treating conditions and illnesses associated with abnormal vasculature | |
US6984655B1 (en) | Photodynamic therapy for selectively closing neovasa in eyeground tissue | |
Shafirstein et al. | Indocyanine green enhanced near‐infrared laser treatment of murine mammary carcinoma | |
Schmidt-Erfurth et al. | Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration | |
US5576013A (en) | Treating vascular and neoplastic tissues | |
Michels et al. | Photodynamic therapy with verteporfin: a new treatment in ophthalmology | |
Woodburn et al. | Photodynamic therapy for choroidal neovascularization: a review | |
Gomer et al. | Photodynamic therapy of intraocular tumors examination of hematoporphyrin derivative distribution and long-term damage in rabbit ocular tissue | |
Shields et al. | Treatment of retinoblastoma with indirect ophthalmoscope laser photocoagulation | |
Young et al. | Photodynamic therapy of pigmented choroidal melanomas using a liposomal preparation of benzoporphyrin derivative | |
Kim et al. | Photodynamic therapy of pigmented choroidal melanomas of greater than 3-mm thickness | |
US6936043B2 (en) | Method to treat age-related macular degeneration | |
Mikvy et al. | Photodynamic therapy of a transplanted pancreatic cancer model using meta-tetrahydroxyphenylchlorin (mTHPC) | |
Journee-de Korver et al. | Thermotherapy in the management of choroidal melanoma | |
Kliman et al. | Retinal and choroidal vessel closure using phthalocyanine photodynamic therapy | |
Obana et al. | Selective occlusion of choroidal neovascularization by photodynamic therapy with a water‐soluble photosensitizer, ATX‐S10 | |
Mori et al. | Photodynamic therapy of experimental choroidal neovascularization with a hydrophilic photosensitizer: mono-L-aspartyl chlorin e6 | |
US20060258629A1 (en) | Photodynamic therapy for ocular neovascularization | |
Gohto et al. | Photodynamic therapy for corneal neovascularization using topically administered ATX-S10 (Na) | |
US20060229284A1 (en) | Enhanced occlusive effect photodynamic therapy | |
Gohto et al. | Treatment parameters for selective occlusion of experimental corneal neovascularization by photodynamic therapy using a water soluble photosensitizer, ATX-S10 (Na) | |
Horsman et al. | Vascular effects of photodynamic therapy in an intraocular retinoblastoma-like tumour | |
Framme et al. | Comparison of reduced and standard light application in photodynamic therapy of the eye in two rabbit models | |
Harada et al. | The vascular response to photodynamic therapy with ATX-S10Na (II) in the normal rat colon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NOVADAQ TECHNOLOGIES INC., CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FLOWER, ROBERT;REEL/FRAME:020637/0795 Effective date: 20031009 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: NOVADAQ CORP., CANADA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:MIDCAP FUNDING IV TRUST (AS SUCCESSOR AGENT TO MIDCAP FINANCIAL TRUST);REEL/FRAME:043786/0344 Effective date: 20170901 Owner name: NOVADAQ TECHNOLOGIES INC., CANADA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:MIDCAP FUNDING IV TRUST (AS SUCCESSOR AGENT TO MIDCAP FINANCIAL TRUST);REEL/FRAME:043786/0344 Effective date: 20170901 Owner name: NOVADAQ TECHNOLOGIES INC., CANADA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:MIDCAP FINANCIAL TRUST;REEL/FRAME:043788/0799 Effective date: 20170901 Owner name: NOVADAQ CORP., CANADA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:MIDCAP FINANCIAL TRUST;REEL/FRAME:043788/0799 Effective date: 20170901 |